
TNDM Stock Forecast & Price Target
TNDM Analyst Ratings
Bulls say
Tandem Diabetes Care is positioned for significant future growth due to a robust product pipeline and strong market presence, evidenced by a 20.6% year-over-year revenue increase to $252.4 million, surpassing consensus expectations. The company anticipates 13-14% revenue growth in the coming year, fueled by warranty renewals, steady supply sales, and growth in new pump starts, indicating its potential as a double-digit revenue growth MedTech firm. Additionally, the recent FDA clearance for Type 2 diabetes products has effectively more than doubled Tandem's addressable market in the U.S., enhancing its growth prospects amid increasing customer satisfaction and retention rates.
Bears say
Tandem Diabetes Care has faced ongoing operating losses since its inception, raising concerns about its ability to achieve sustained profitability amidst a backdrop of uncertain market conditions. The company's recent revenue guidance for 2025 appears underwhelming, reflecting seasonal trends and potential disruptions, while its gross margins have fallen short of consensus expectations, further highlighting financial strain. Additionally, various downside risks, such as slower market expansion, increased competition, reimbursement challenges, and ineffective R&D, contribute to a negative outlook for the stock.
This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.
TNDM Analyst Forecast & Price Prediction
Start investing in TNDM
Order type
Buy in
Order amount
Est. shares
0 shares